367 related articles for article (PubMed ID: 36172359)
1. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers.
Liu X; Xu X; Wu Z; Shan Q; Wang Z; Wu Z; Ding X; Huang W; Wang Z
Front Immunol; 2022; 13():961350. PubMed ID: 36172359
[TBL] [Abstract][Full Text] [Related]
2. Comparative analyses of the prognosis, tumor immune microenvironment, and drug treatment response between left-sided and right-sided colon cancer by integrating scRNA-seq and bulk RNA-seq data.
Cao L; Zhang S; Yao D; Ba Y; Weng Q; Yang J; Zhang H; Ren Y
Aging (Albany NY); 2023 Jul; 15(14):7098-7123. PubMed ID: 37480572
[TBL] [Abstract][Full Text] [Related]
3. Mathematical modeling the order of driver gene mutations in colorectal cancer.
Li L; Hu Y; Xu Y; Tang S
PLoS Comput Biol; 2023 Jun; 19(6):e1011225. PubMed ID: 37368936
[TBL] [Abstract][Full Text] [Related]
4. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
[No Abstract] [Full Text] [Related]
5. Integrated multi-omics characterization of KRAS mutant colorectal cancer.
Chong W; Zhu X; Ren H; Ye C; Xu K; Wang Z; Jia S; Shang L; Li L; Chen H
Theranostics; 2022; 12(11):5138-5154. PubMed ID: 35836817
[TBL] [Abstract][Full Text] [Related]
6. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
8. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
9. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.
Liu J; Huang X; Liu H; Wei C; Ru H; Qin H; Lai H; Meng Y; Wu G; Xie W; Mo X; Johnson CH; Zhang Y; Tang W
J Transl Med; 2021 Jan; 19(1):27. PubMed ID: 33413474
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
11. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
12. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
[TBL] [Abstract][Full Text] [Related]
13. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract][Full Text] [Related]
14. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
15. Targeting nucleotide metabolic pathways in colorectal cancer by integrating scRNA-seq, spatial transcriptome, and bulk RNA-seq data.
Zhao S; Zhang P; Niu S; Xie J; Liu Y; Liu Y; Zhao N; Cheng C; Lu P
Funct Integr Genomics; 2024 Apr; 24(2):72. PubMed ID: 38594466
[TBL] [Abstract][Full Text] [Related]
16. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
17. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).
Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R
BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682
[TBL] [Abstract][Full Text] [Related]
18. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer.
Datta J; Bianchi A; De Castro Silva I; Deshpande NU; Cao LL; Mehra S; Singh S; Rafie C; Sun X; Chen X; Dai X; Colaprico A; Sharma P; Dosch AR; Pillai A; Hosein PJ; Nagathihalli NS; Komanduri KV; Wilson JM; Ban Y; Merchant NB
Oncogene; 2022 Jul; 41(28):3640-3654. PubMed ID: 35701533
[TBL] [Abstract][Full Text] [Related]
19. Integration of single-cell RNA sequencing and bulk RNA transcriptome sequencing reveals a heterogeneous immune landscape and pivotal cell subpopulations associated with colorectal cancer prognosis.
Zhang Q; Liu Y; Wang X; Zhang C; Hou M; Liu Y
Front Immunol; 2023; 14():1184167. PubMed ID: 37675100
[TBL] [Abstract][Full Text] [Related]
20. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
